Neumora grants chair 500K stock options at $1.52

Q: What equity award did Paul L. Berns receive from NMRA in this Form 4?

Paul L. Berns received a stock option grant for 500,000 shares of Neumora Therapeutics, Inc. common stock, reported as a derivative security held directly following the transaction.

Q: What is the exercise price and expiration date of the NMRA options granted to Paul L. Berns?

The options have an exercise price of $1.52 per share and an expiration date of August 20, 2036, as disclosed for the 500,000-share stock option grant.

Q: How do the NMRA options granted to Paul L. Berns vest?

The options vest 25% on the first anniversary of August 20, 2026. Thereafter, 1/48 of the total shares vest monthly until the options are 100% vested on the fourth anniversary of the Vesting Commencement Date.

Q: How many NMRA derivative securities does Paul L. Berns hold after this transaction?

Following the reported transaction, Paul L. Berns holds 500,000 derivative securities in the form of stock options, corresponding to 500,000 underlying shares of Neumora Therapeutics, Inc. common stock.

Q: Is this NMRA Form 4 transaction a purchase or a grant of options?

The filing reports a grant/award acquisition of stock options, coded as an "A" transaction, rather than an open-market purchase or sale. It reflects an equity award to Paul L. Berns as Executive Chair of the Board.

Neumora Therapeutics, Inc. (NMRA) reported that Executive Chair of the Board Paul L. Berns received a stock option grant covering 500,000 shares of common stock at an exercise price of $1.52 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) reported that Executive Chair of the Board Paul L. Berns received a stock option grant covering 500,000 shares of common stock at an exercise price of $1.52 per share. The option expires on August 20, 2036 and is held as a direct derivative position.

According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of August 20, 2026, and 1/48 of the total shares vest monthly thereafter so that the option becomes fully vested on the fourth anniversary of the Vesting Commencement Date.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 1 txn

Insider BERNS PAUL L

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 500,000 contracts (Direct)

Footnotes (1)

F1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Key Figures

Stock options granted: 500,000 shares Exercise price: $1.52 per share Underlying common shares: 500,000 shares +3 more

6 metrics

Stock options granted 500,000 shares Stock Option (Right to Buy) granted to Paul L. Berns

Exercise price $1.52 per share Conversion or exercise price of the granted stock option

Underlying common shares 500,000 shares Underlying Neumora Therapeutics, Inc. common stock for the option

Option expiration date August 20, 2036 Expiration date of the granted stock option

Initial vesting tranche 25% of shares Vests on first anniversary of August 20, 2026

Ongoing vesting rate 1/48 of total shares monthly Monthly vesting after first anniversary until fully vested

Key Terms

Stock Option (Right to Buy), Vesting Commencement Date, fully vested and exercisable

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Vesting Commencement Date financial

"measured from August 20, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable financial

"100% of the shares subject to the option will be fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Paul L. Berns receive from NMRA in this Form 4?

Paul L. Berns received a stock option grant for 500,000 shares of Neumora Therapeutics, Inc. common stock, reported as a derivative security held directly following the transaction.

What is the exercise price and expiration date of the NMRA options granted to Paul L. Berns?

The options have an exercise price of $1.52 per share and an expiration date of August 20, 2036, as disclosed for the 500,000-share stock option grant.

How do the NMRA options granted to Paul L. Berns vest?

The options vest 25% on the first anniversary of August 20, 2026. Thereafter, 1/48 of the total shares vest monthly until the options are 100% vested on the fourth anniversary of the Vesting Commencement Date.

How many NMRA derivative securities does Paul L. Berns hold after this transaction?

Following the reported transaction, Paul L. Berns holds 500,000 derivative securities in the form of stock options, corresponding to 500,000 underlying shares of Neumora Therapeutics, Inc. common stock.

Is this NMRA Form 4 transaction a purchase or a grant of options?

The filing reports a grant/award acquisition of stock options, coded as an "A" transaction, rather than an open-market purchase or sale. It reflects an equity award to Paul L. Berns as Executive Chair of the Board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/21/2026 - 07:10 PM EDT Accepted by SEC EDGAR 08/21/2026 - 07:10 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BERNS PAUL L

(Last)

(First)

(Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.52	08/20/2026		A		500,000		⁽¹⁾	08/20/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Executive Chair of the Board

	/s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR